[Asia Economy Reporter Hyunseok Yoo] Saltlux announced on the 23rd that it will officially enter the bio-health sector, which it has been preparing for over a year, starting with its participation in Ulsan City's Genome Service Industry Regulatory Free Zone Project (hereinafter referred to as the Genome Free Zone Project).
The artificial intelligence (AI) company Saltlux has confirmed its participation in the "Development of Intelligent Bio-Omics Analysis Technology" project, which is part of Ulsan City's Genome Free Zone Project. Since 2019, Saltlux has been preparing to apply AI to the bio and biotechnology fields. Together with Ulsan City, it has spent the past year preparing for business establishment and technology development.
The Genome Free Zone Project, which will be conducted over two years starting this year with a total budget of 40.7 billion KRW, will have Saltlux responsible for developing AI technologies necessary for biomarkers in new drug development and a platform for analyzing ultra-large-scale big data. Saltlux's natural language processing as well as technologies for analyzing national-scale massive bio big data will be comprehensively applied.
Additionally, Saltlux plans to actively enter the bio business field aimed at overcoming cancer and preventing aging through collaboration with Clinomics, a next-generation genome-based diagnostic specialist company that went public after Saltlux's investment last year. Considering the global growth potential of the business, Saltlux is seeking cooperation not only with domestic but also global companies. Related business expansion plans are expected to be announced in the second half of this year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
